Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration

Table 1 Comparison of the half-life and PPARγ binding affinities of MSDC-0160 and commonly used TZDs

Drug	PPARγ binding IC₅₀(μM)	MPC binding (μM)	C _max /half life
Rosiglitazone	0.112	1.1	1 µM/3–4 h
Pioglitazone	1.535	1.2	4 µM/5–8 h
MSDC-0160	31.648	1.2	12 µM/12 h

ISSN: 1750-1326